Multiple Sclerosis Clinical Trials in Los Angeles

Showing 441-460 of 489 trials

EPO906 Therapy in Patients With Advanced Kidney Cancer

NCT00035243

This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause kidney cancer.

Kidney Neoplasms

Novartis Pharmaceuticals53 participantsStarted Apr 2002

Los Angeles, California, United States • Baltimore, Maryland, United States • Detroit, Michigan, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

NCT00649792

The purpose of the study is to evaluate the safety, tolerability and activity of Fampridine-SR when administered for up to 36 additional months in patients who previously participated in the MS-F204 study or until it becomes commercially available, whichever comes first.

Multiple Sclerosis

Acorda Therapeutics214 participantsStarted Aug 2007

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Fayetteville, Arkansas, United States +39 more locations

EPO906 Therapy in Patients With Advanced Kidney Cancer

Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral Fampridine-SR in Patients With Multiple Sclerosis Who Participated in the MS-F204 Trial

Multiple Sclerosis Trials in Other Cities

Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)

Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis

A Phase III Trial For Patients With Metastatic Breast Cancer

Study of the Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Thyroid Cancer

A Safety And Pharmacokinetic Study With CVX-045 In Patients With Advanced Solid Tumors

YM598 Added to Mitoxantrone/Prednisone to Control Pain in Metastatic Prostate Cancer Patients No Longer Responding to Hormone Therapy

A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose

Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

A Study of MF101 in Postmenopausal Women

Effect of Cabazitaxel on the QTc Interval in Cancer Patients

A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies

Placebo Controlled Study in Subjects With Relapsing Forms of MS to Evaluate the Safety, Tolerability and Effects of CDP323

Nexium Dyspepsia/AST

Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer

Investigational Agent AG-013736 In Combinations With Standard Of Care Treatments For Patient's With Advanced Solid Tumor

Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis

Other Conditions in Los Angeles